Leading the Way in Life Science Technologies

GEN Exclusives

More »

Best of the Web

More »
Apr 01, 2007 (Vol. 27, No. 7)

Database of Ribosomal Crosslinks

URL:www.molgen.mpg.de/~ag_ribo/ag_brimacombe/drc/
  • Useful research info
  • Dreadful interface with information
Since the title here isn’t overly informative, I’ll need to provide a bit of background. A powerful tool for studying molecular interactions is cross-linking. In this method, molecules are allowed to interact and then a chemical agent is introduced/activated that makes a covalent bond between structures close to each other. Thus, in the case of a ribosome, one can see which proteins are in close proximity by cross-linking and then assaying them to see which ones end up attached to each other by the crosslinker. The Database of Ribosomal Crosslinks is aimed at providing researchers with access to such experimental data. Yes, the site is a bit out of date, but the data is not, so I include it here for reference. Be forewarned—the information is not in a user-friendly format. Researchers outside of this field will have a hard time interpreting the contents.
  • Key:
  • Strong Points
  • Weak Points
  • Ratings:
  • Excellent
  • Very Good
  • Good


*The opinions expressed are solely those of the author(s) and should not be construed as reflecting the viewpoints of the publisher, Genetic Engineering & Biotechnology News, Mary Ann Liebert, Inc., the publishing house, or employees and affiliates thereof.

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »